Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21\textsuperscript{WAFl/CIP1} in pancreatic cancer

N Harada\textsuperscript{1,2}, S Gansauge\textsuperscript{1}, F Gansauge\textsuperscript{1}, H Gause\textsuperscript{1}, S Shimoyama\textsuperscript{1}, T Imaizumi\textsuperscript{2}, T Mattfeld\textsuperscript{4}, MH Schoenberg\textsuperscript{1} and HG Beger\textsuperscript{1}

\textsuperscript{1}Department of General Surgery, University of Ulm, Germany; \textsuperscript{2}Department of Gastroenterological Surgery, Tokyo Women's Medical College, Japan; \textsuperscript{3}The Third Department of Surgery, Tokyo University, Japan; \textsuperscript{4}Department of Pathology, University of Ulm, Germany

Summary Recent studies have suggested a p53-independent expression of p21\textsuperscript{WAFl/CIP1}. We investigated the correlation between p53 overexpression and the expression of p21\textsuperscript{WAFl/CIP1} in 57 patients with pancreatic adenocarcinoma. By means of reverse transcription and polymerase chain reaction (RT-PCR), we examined the mRNA levels of WAFl/CIP1 and compared them with the p53 status in 20 patients and in a further six pancreatic tumour cell lines. In pancreatic cancer tissues, immunohistological evaluation revealed a significant correlation between active p53 and p21\textsuperscript{WAFl/CIP1} (P < 0.005) as well as WAFl/CIP1 mRNA expression (P < 0.005). This coherence was also evident in human pancreatic carcinoma cell lines. The analysis of p53 and p21\textsuperscript{WAFl/CIP1} expression in relation to clinicopathological features revealed a significant correlation between p53 overexpression and tumour stage, tumour size, grading and lymph node metastases, whereas p21\textsuperscript{WAFl/CIP1} expression correlated only with tumour size. We conclude that the expression of p21\textsuperscript{WAFl/CIP1} normally depends on active p53, but that there may also exist p53-independent pathways of induction that reduce the correlation of p21\textsuperscript{WAFl/CIP1} to clinicopathological features.

Keywords: pancreatic cancer; pancreatic cancer cell line; p53; WAFl/CIP1

Inactivation of the p53 tumour-suppressor gene is a frequent genetic abnormality in human cancers (Hollstein et al, 1991). The wild-type p53 gene encodes a 53-kDa nuclear phosphoprotein that is involved in the regulation of the cell cycle and apoptosis. Its abnormalities are thought to contribute to tumour development (Kastan et al, 1992). Since the finding that p53 could bind to DNA in a sequence-specific manner and activate other genes (Kern et al, 1991; Vogelstein et al, 1992), the downstream regulation of the p53-suppressing function has been vigorously investigated. p21\textsuperscript{WAFl/CIP1} was originally described as a potent inhibitor of cyclin-dependent kinases (Harper et al, 1993) and at the same time was reported as being a M\textsubscript{r} 21 000 protein transcriptionally activated by wild-type p53 (el Deiry et al, 1993). Subsequent studies supported this p53-dependent expression of p21\textsuperscript{WAFl/CIP1} (Kern et al, 1991; el Deiry et al, 1994). However, recent studies have suggested that there is a p53-independent pathway to induce the expression of p21\textsuperscript{WAFl/CIP1} in muscle and other terminally differentiating cells (Parker et al, 1995) in pancreatic carcinoma (DiGiuseppe et al, 1995) and in leukaemic cells (Schwaller et al, 1995). In the present study, we investigated the correlation between p53 overexpression and the expression of p21\textsuperscript{WAFl/CIP1} as well as p21\textsuperscript{WAFl/CIP1} messenger RNA (mRNA) levels in pancreatic ductal adenocarcinoma tissues and pancreatic cancer cell lines. Furthermore, we were able to induce WAFl/CIP1 in a cell line containing mutant p53 under serum starvation or hypoxic conditions. Our results demonstrate a statistically significant correlation between p21\textsuperscript{WAFl/CIP1} and active p53 in human pancreatic cancer, supporting the hypothesis that the suppressor function of p53 could be mediated through the induction of WAFl/CIP1 (el Deiry et al, 1993; Harper et al, 1993).

MATERIALS AND METHODS

Patients and tissues

The group of patients with ductal adenocarcinomas of the pancreas included 57 patients who had undergone a pancreaticoduodenectomy or left resection of the pancreas at the Department of General Surgery, University of Ulm. The mean age of the patients was 61.7 years, with a range from 39 to 86 years. Tissues were collected immediately after surgical removal, snap-frozen in liquid nitrogen and stored at −80°C, or they were fixed in 4% formalin for 1 day at room temperature, processed and embedded in paraffin.

Pancreatic cancer cell lines and culture condition

Human pancreatic adenocarcinoma cell lines Capan-1, Capan-2, AsPC-1, BxPC-3 and MIA PaCa-2 were obtained from the...
Table 1 Correlation between p53 overexpression and p21 protein expression in 57 cases of pancreatic carcinoma (P < 0.005)

| p53 accumulation | Positive | Negative | Total |
|-------------------|----------|----------|-------|
| Negative          | 22       | 12       | 34    |
| Positive          | 6        | 17       | 23 (40%) |
| Total             | 28 (49%) | 29       | 57    |

Figure 1 Immunohistochemistry of serial sections of pancreatic ductal adenocarcinoma tissue with negative p53 staining. No p53 staining was achieved (A) whereas p21\(^{WAF1/CIP1}\) was expressed at corresponding sites (B)

American Type Culture Collection (Rockville, MD, USA), and PMH2/89 was established in our laboratory. Cell lines were incubated in RPMI-1640 medium (GIBCO BRL) supplemented with 10% heat-inactivated fetal bovine serum and 0.5% penicillin and streptomycin in a humidified incubator at 37°C in an atmosphere of 5% carbon dioxide and 95% air. Approximately 1 x 10\(^6\) cells of each cell line were enzymatically harvested and were subjected to isolation of mRNA. For further investigation, 1 x 10\(^6\) BxPC3 cells in each 10-cm Petri dish were cultured with 7 ml of medium for 48 h. Three dishes containing 1 x 10\(^6\) cells were incubated under different conditions: in the control sample, medium was changed at 24 h; in the second sample, medium was not changed for 48 h; and in the third one, medium was not changed for 48 h and air was replaced with 100% carbon dioxide gas to displace oxygen and induce hypoxic conditions. After a 48-h incubation, 1 x 10\(^6\) cells of each dish were harvested and used for extraction of mRNA or protein samples.

Immunohistochemistry

Consecutive 5-µm-thick paraffin-embedded sections were placed on 1% silane-coated slide glasses and were boiled up in 0.2% citrate buffer for 20 min. The two specific monoclonal antibodies DO1 and WAF1 (Oncogene Science, MA, USA), which recognize human p53 protein or WAF1/CIP1 protein (p21\(^{WAF1/CIP1}\)), respectively, were used for immunohistochemical staining. Optimal results for DO1 were obtained at an antibody dilution of 1:500 and for p21\(^{WAF1/CIP1}\) at an antibody dilution of 1:25. The primary antibody was detected with a biotinylated anti-mouse IgG secondary antibody and streptavidin–peroxidase complex (Dako, Denmark), followed by incubation with diaminobenzidine tetrahydrochloride as the substrate. The slides were counterstained with Mayer’s haemalum. On the basis of microscopic observation, staining for both p53 and p21\(^{WAF1/CIP1}\) were graded as absent, focal or diffuse.

Enzyme-linked immunosorbent assay (ELISA)

Protein lysates were extracted from 100 mg of frozen pancreatic adenocarcinoma tissues using lysis buffer (50 mM Tris- HCl, 150 mM sodium chloride, 10 mM EDTA, 1% nonylphenyl-polyethylene
WAF1 correlates inversely with p53 overexpression in pancreatic cancer

Figure 3 Quantitative p53 and WAF1/CIP1 determination in pancreatic carcinoma tissues in relation to the immunohistological results. Tissues with a p53 overexpression in immunohistochemistry showed significantly higher p53 levels in ELISA than p53-negative tissues ($P = 0.001$). Similar results were obtained in p21$^{WAF1/CIP1}$ tissue concentrations compared with immunohistology ($P = 0.002$).

Table 2 Correlation between p53 overexpression and WAF1/CIP1 protein and mRNA expression in 20 cases of pancreatic carcinoma

| p53 accumulation | WAF1/CIP1 mRNA expression | WAF1/CIP1 protein expression |
|------------------|---------------------------|-----------------------------|
|                  | Positive | Negative | P-value | Positive | Negative | P-value |
| Negative         | 13     | 2        |         | 7       | 8        |         |
| Positive         | 1      | 4        |         | 0       | 5        |         |
| Total            | 14     | 6        | $P < 0.005$ | 7       | 13       | $P < 0.05$ |

Western blot analysis

For Western blot analysis, $1 \times 10^6$ cells of each sample were washed three times with phosphate-buffered saline (PBS) and protein was extracted as described above. After denaturation at 95°C for 5 min, 100 μg of protein per lane were electrophoresed on a sodium dodecyl sulphate (SDS)-polyacrylamide gel and transferred to nitrocellulose membranes. The membranes were blocked with PBS containing 5% dried milk and 0.1% Tween-20 and then probed with the p53 monoclonal antibody DO-1 (Oncogene Science). After washing in PBS containing 0.1% Tween-20 and subsequent incubation with horseradish peroxidase-linked anti-mouse second antibody, specific complexes were detected using a chemiluminescent technique (ECL, Amersham Life Science).

Reverse transcription and polymerase chain reaction

Messenger RNA (mRNA) was isolated from 100 mg of frozen tissue or $1 \times 10^6$ cells of trypsinized cell line using a guanidinium thiocyanate method and oligo(dT)-cellulose column chromatography (QuickPrep Micro mRNA Purification Kit, Pharmacia Biotech) and dissolved in the elution buffer provided in the kit in a final volume of 30 μl.

Complementary DNA (cDNA) was prepared by reverse transcription (RT) of mRNA (5 μl) using SuperScript RT RNAase H-Reverse Transcriptase (GIBCO BRL) and diluted with distilled water in a final
volume of 50 μl. WAF1/CIP1 sequences were amplified using the following primers: 5'-AGGATCCATGTCAGAACCGGCTGG-3' and 5'-CAGGATCCTGTGGGCGGATTAGGGCT-3'. A 6-μl aliquot of cDNA was amplified with 0.125 μl of each primer in a reaction mix comprising 4 μl of 10× PCR buffer, 2.5 mM dNTPs and 5 units of Taq polymerase (Perkin Elmer) in a final volume of 40 μl. Following denaturation at 94°C for 3 min, 31 cycles of amplification consisting of denaturation (1 min at 94°C), annealing (1 min at 60°C) and elongation (1 min at 72°C) were followed by a final extension reaction at 72°C for 5 min. The 520-bp PCR products were electrophoresed on 1.25% small DNA agarose gels containing ethidium bromide and visualized under ultraviolet light. B-Actin was used as an internal standard in each experiment to confirm equal loading of the gel, according to a recently published protocol (du-Breuil et al, 1993).

Statistical analysis

Results are expressed as mean values [± standard error (s.e.)]. For statistical analysis, chi-square test, Fisher's exact test and unpaired student t-test were used. Significance was defined as P < 0.05.

RESULTS

Immunohistochemistry of pancreatic cancer tissues

Immunohistochemical analysis of pancreatic ductal adenocarcinoma tissues using DO-1 antibody directed against both wild-type p53 and mutant p53 proteins revealed positive nuclear immunoreactivity in 40% (23 of 57). The anti-p21WAF1/CIP1 antibody stained 49% (28 of 57) of the tissues (Table 1). Twenty-two of the 34 patients with p53-negative staining (65%) expressed positive nuclear staining for p21WAF1/CIP1 (Figure 1). In contrast, of the 23 patients with p53-positive staining, 17 patients (74%) did not show any immunoreactivity for p21WAF1/CIP1 (Figure 2). However, positive staining for p21WAF1/CIP1 was detectable in six patients (26%) with p53 overexpression. Statistical analysis of these data indicated that the expression of p21WAF1/CIP1 correlated significantly with p53 protein overexpression in pancreatic ductal adenocarcinoma tissues (P < 0.005).

ELISA analysis of pancreatic cancer tissues

ELISA analysis for both p53 and p21WAF1/CIP1 were performed in 20 pancreatic adenocarcinoma tissues. The mean p53 level in the samples with positive immunoreactivity for DO1 antibody was 1390 ± 630 pg ml⁻¹ and in the samples with negative immunoreactivity was 100 ± 80 pg ml⁻¹. The mean p21WAF1/CIP1 level in the samples with positive immunoreactivity for p21WAF1/CIP1 antibody was 4.9 ± 0.8 U ml⁻¹, while in the samples with negative immunoreactivity the mean level was 1.9 ± 0.4 U ml⁻¹ (Figure 3). A statistical significance was noted between immunohistochemistry and ELISA analysis in both p53 (P < 0.001) and p21WAF1/CIP1 (P < 0.002).
Table 3 Clinopathological features of p21 and p53 expression

|                | p53 |                |            |            | p21 |                |            |            |
|----------------|-----|----------------|------------|------------|-----|----------------|------------|------------|
|                | Negative | Positive | P-value | Negative | Positive | P-value |            |            |
| Total          | 34  | 23             |          | 29        | 28        |          |            |            |
| Sex            |      |                |          |           |          |          |            |            |
| Male           | 19  | 10             |          | 14        | 15        |          |          |            |
| Female         | 15  | 13             | 0.25     | 15        | 13        | 0.45     |          |            |
| Stage (UICC)   |      |                |          |           |          |          |            |            |
| Stage I and II | 12  | 1              |          | 7         | 6         |          |          |            |
| Stage III      | 17  | 20             | I and II vs III and IV | 18 | 19 | I and II vs III and IV |          |            |
| Stage IV       | 5   | 2              | 0.005    | 4         | 3         | 0.8      |          |            |
| Tumour primary |      |                |          |           |          |          |            |            |
| T1             | 5   | 0              |          | 2         | 3         |          |          |            |
| T2             | 20  | 8              | T1 and T2 vs T3 | 10 | 18 | T1 and T2 vs T3 |          |            |
| T3             | 9   | 15             | 0.004    | 17        | 7         | 0.01     |          |            |
| Lymph nodes    |      |                |          |           |          |          |            |            |
| Negative       | 13  | 1              |          | 7         | 7         |          |          |            |
| Positive       | 21  | 22             | 0.003    | 22        | 21        | 0.93     |          |            |
| Metastases     |      |                |          |           |          |          |            |            |
| Negative       | 29  | 21             |          | 25        | 25        |          |          |            |
| Positive       | 5   | 2              | 0.49     | 4         | 3         | 0.72     |          |            |
| Grade          |      |                |          |           |          |          |            |            |
| G1             | 2   | 0              |          | 1         | 1         |          |          |            |
| G2             | 25  | 11             | G1 and G2 vs G3 | 16 | 20 | G1 and G2 vs G3 |          |            |
| G3             | 7   | 12             | 0.014    | 12        | 7         | 0.15     |          |            |
| Survival (months) | 16  | 10.5          | 0.08     | 12        | 15        | 0.14     |          |            |

G, grade (G1, well differentiated; G2, moderately differentiated; G3, undifferentiated).

RT-PCR analysis of pancreatic cancer tissues

In order to investigate whether there was a correlation between negative p53 immunoreactivity and WAF1/CIP1 mRNA expression, RT-PCR analyses were carried out in 20 pancreatic adenocarcinoma tissues. Of the 15 tissues not overexpressing p53 protein, 13 tissues (87%) exhibited WAF1/CIP1 mRNA signals, including seven tissues with positive p21WAF1/CIP1 staining (Table 2). On the other hand, of the five tissues overexpressing p53 protein, only one tissue revealed a positive WAF1/CIP1 mRNA signal and none of these tissues showed p21WAF1/CIP1 (Figure 4). Statistical analysis of these data also indicated a significant correlation of WAF1/CIP1 mRNA expression with negative p53 immunoactivity in pancreatic ductal adenocarcinoma tissues (P < 0.005).

RT-PCR analysis of pancreatic cancer cell lines

Six human pancreatic adenocarcinoma cell lines Capan-2, AsPC-1, PMH2, Capan-1, BxPC-3 and MIA PaCa-2 were used for the investigation of the WAF1/CIP1 mRNA expression. In Capan-1, BxPC-3 and MIA PaCa-2, p53 mutations in exon 5, exon 6 and exon 7 were confirmed by single-strand conformation polymorphism (SSCP) respectively. In the other cell lines, no p53 mutation was detectable (data not shown). The three cell lines with wild-type p53, i.e. Capan-2, AsPC-1 and PMH2, exhibited clear PCR signals of amplified WAF1/CIP1 cDNA, whereas the cell lines bearing mutant p53, i.e. Capan-1, BxPC-3 and MIA PaCa-2, showed only faint or no PCR signals (Figure 5).

Induction of WAF1/CIP1 in the pancreatic carcinoma cell line BxPC-3

To further investigate the induction of p21WAF1/CIP1, we cultured BxPC-3 containing mutant p53 under three different conditions: with fresh medium (control, F), with medium left for 48 h (S) and with medium left for 48 h in an hypoxic, hypercapnic atmosphere of 100% carbon dioxide (SH). In Western blot analysis for p53, both sample S and sample SH exhibited distinct accumulation of p53 protein compared with the control sample F. RT-PCR analysis also revealed an increasing expression of WAF1/CIP1 mRNA in the samples S and SH (Figure 6).

Clinical correlations of p53 and p21WAF1/CIP1 expression in pancreatic cancer

Similar to previous reports (Pellegata et al, 1994; Gansauge et al, 1996), p53 overexpression was significantly more frequent in advanced stages (UICC stage III and IV), tumours that had already infiltrated adjacent structures (T3) and had metastasized in regional lymph nodes (N1). p53 overexpression was also significantly more often observed in undifferentiated tumours (G3) (Table 3). These correlations were also reflected in terms of patients' survival (p53 positive, 10.5 months; p53 negative, 16 months). Although p53 overexpression correlated significantly with absent expression of p21WAF1/CIP1 (P < 0.005), correlations of p21WAF1/CIP1 expression to clinicopathological features were reduced compared with p53 overexpression; the only significant
correlation of p21\textsuperscript{WAF1/CIP1} was found with the T stage. p21\textsuperscript{WAF1/CIP1} was significantly more frequently found in tumours that had not infiltrated adjacent structures (Table 3).

**DISCUSSION**

p21\textsuperscript{WAF1/CIP1} seems to be essential in the p53-mediated arrest of the cell cycle in response to DNA damage (Xiong et al., 1993; Dulic et al., 1994; el Deiry et al., 1994). Although the WAF1/CIP1 promoter has a p53 binding site and WAF1/CIP1 transcription is activated by wild-type p53 (el Deiry et al., 1993), WAF1/CIP1 can also be activated by p53-independent factors, as p21\textsuperscript{WAF1/CIP1} is also inducible in p53-null cell (Michieli et al., 1994). A better understanding of cell cycle regulation and apoptotic mechanisms in cancer cells in particular would improve anti-cancer therapy as many tumour cells that lack functional p53 are not able to undergo apoptosis in response to DNA-damaging drugs or radiation (Fisher, 1994). In pancreatic cancer, several groups have examined the status of p53, either by sequencing the gene or by immunohistochemical assessment of the p53 protein (Barton et al., 1991; Casey et al., 1993; Lee et al., 1993; Scarpa et al., 1993; Pellegrata et al., 1994; Redston et al., 1994; DiGiuseppe et al., 1995; Gansauge et al., 1996).

Immunohistochemical detection of p53 is based on the evidence that the p53 protein in normal adult tissues and in cancer tissues with the wild-type p53 gene has a half-life of about 20 min (Finlay et al., 1988), whereas mutant p53 can be stable for hours. As immunohistochemistry alone is only an approximation to the real mutation rate, it may underestimate the mutation frequency of the p53 gene, especially with regard to deletions or non-sense mutations in the p53 gene that do not lead to p53 immunoreactivity (Borresen et al., 1991). In some cases this could probably explain why some tissues that seem to be wild type in immunohistochemistry do not correspond to the expected p21\textsuperscript{WAF1/CIP1} expression. On the other hand recent reports have shown that the accumulation of p53 is not always due to mutations in the gene (Bourdon et al., 1995), implying that stabilization of the p53 protein can also lead to an overexpression of p53 as shown by others (Wynford-Thomas, 1992). However, many comparative studies have shown that p53 overexpression is a good approximation to the real mutation rate (Hall et al., 1991; Melhem et al., 1995; Nishio et al., 1996) with approximately 90% concordance between immunostaining and gene analysis (Nishio et al., 1996) and a specificity of immunohistochemistry of 91% (Melhem et al., 1995). In addition, the immunohistochemical evidence of the p21\textsuperscript{WAF1/CIP1} expression could depend on the mutational status of the WAF1/CIP1 protein itself. However, WAF1/CIP1 alterations seem to be rare in human malignancies (Shiohara et al., 1994).

In the present series of surgically resected pancreatic adenocarcinoma tissues, p53 negativity in immunohistochemistry correlated not only with p21\textsuperscript{WAF1/CIP1} expression (P < 0.005) but also with WAF1/CIP1 mRNA expression (P < 0.005), which supports the hypothesis that wt p53 transactivates the WAF1/CIP1 gene (el Deiry et al., 1993; Dulic et al., 1994). However, in 11% (6/57) of the cases investigated, p21\textsuperscript{WAF1/CIP1} protein was immunohistochemically detectable despite a concomitant p53 accumulation, pointing to existing p53 mutations or at least to p53 inactivation; either p21\textsuperscript{WAF1/CIP1} expression was induced in a p53-independent pathway (Michieli et al., 1994; Akashi et al., 1995) or the underlying p53 mutations in some cases still permitted the transactivation of the WAF1/CIP1 gene.

In recent approaches it has been shown that not all mutations of p53 correlate with a loss of transactivation activity (Ory et al., 1994). In general it has been assumed that mutated p53 proteins exert a dominant negative effect on wt p53 functions. Forrester and colleagues (1995) recently reported that these effects could be cell-type dependent up to a minimal dominant negative effect of transfectant mutants on co-transfected wt p53 (Forrester et al., 1995); although it is possible that an up-regulation of wt p53 leads to the transactivation of the WAF1/CIP1 gene as it is known that p53 levels increase under serum starvation conditions in different cell types. In our cell line experiments, we could demonstrate an up-regulation of p53 under serum starvation conditions accompanied by an increase of WAF1/CIP1 mRNA and p21\textsuperscript{WAF1/CIP1} in the cell line BxPC 3, which is mutated in the p53 gene (Barton et al., 1991).

The analysis of p53 and p21\textsuperscript{WAF1/CIP1} in relation to clinicopathological features revealed a significant correlation between p53 overexpression and tumour stage as well as tumour size, grading and lymph node metastases, as also shown elsewhere (Pellegrata et al., 1994; Gansauge et al., 1996). p53 accumulation seems to correlate with poor prognosis (10.5 vs 16 months), although in our study this relationship did not reach statistical significance. As WAF1/CIP1 is a downstream effector of p53 and is induced in G1 arrest and apoptosis (el Deiry et al., 1994), which mediates growth-regulatory functions of p53, one would expect p21\textsuperscript{WAF1/CIP1} to be a supplementary factor for describing more precisely the effects of p53 than does p53 accumulation concerning clinicopathological features. However, analysis of p21\textsuperscript{WAF1/CIP1} showed only a poor correlation between protein expression and clinical outcome despite the significant correlation between p53 and p21\textsuperscript{WAF1/CIP1} expression, which implies the possibility of bypassing the normally p53-dependent p21\textsuperscript{WAF1/CIP1} induction under some physiological conditions in pancreatic carcinoma. As the p21\textsuperscript{WAF1/CIP1} increase occurring under these appropriate conditions could be temporary, the immunohistochemical expression of p21\textsuperscript{WAF1/CIP1} fails to correlate with clinical data but not in the same manner as p53 overexpression, which is mainly because of persistent genetic changes.

**ACKNOWLEDGEMENT**

This work was supported by grant no. GA 541/1-1 to Susanne Gansauge from the Deutsche Forschungsgemeinschaft.

**REFERENCES**

Akashi M, Hachiya M, Osawa Y, Spirin K, Suzuki G and Koeffler HP (1995) Irradiation induces WAF 1 expression through a p53-independent pathway in KG-1 cells. *J Biol Chem* 270: 19181–19187

Barton CM, Staddon SL, Hughes CM, Hall PA, O’Sullivan C, Kloppel G, Theis B, Russell RCG, Neoptolemos J, Williamson RCN, Lane DP and Lemoine NR (1991) Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. *Br J Cancer* 64: 1076–1082

Borresen AL, Hovig E, Smith Sorensen B, Malkin D, Lystad S, Andersen Tl, Nesland JM, Isselbacher KJ and Friend SH (1991) Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. *Proc Natl Acad Sci USA* 88: 8405–8409

Bourdon JC, D’Errico A, Paerelti P, Grigioni W, May E and Debuire B (1995) p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. *Gastroenterology* 108: 1176–1182

Casey G, Yamanaka Y, Friess H, Korbirn MS, Lopez ME, Buchler M, Beger HG and Korc M (1993) p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. *Cancer Lett* 69: 151–160

DiGiuseppe JA, Redston MS, Yeo C, Kern SE and Hruban RH (1995) p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. *Am J Pathol* 147: 884–888

© Cancer Research Campaign 1997
Du-Breuil RM, Patel JM and Mendelow BY (1993) Quantitation of beta-actin-specific mRNA transcripts using xeno-competitive PCR. PCR Methods Appl 3: 57–59

Dulic V, Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ and Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013–1023

El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumour suppression. Cell 78: 817–825

El Deiry WS, Harper JW, O’Connor PM, Velculescu VE, Canman CE, Jackman JM, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wilman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174

Finlay CA, Hinds PW, Tan T-H, Elyahu D, Oren M and Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms a bc570-p53 complex with an altered half life. Mol Cell Biol 8: 531–539

Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539–542

Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW and Harris CC (1995) Effects of p53 mutants on wild-type p53 mediated transactivation are cell type dependent. Oncogene 10: 2103–2111

Gansauge S, Gansauge F, Negri G, Galle P, Müller J, Poch B, Nüssler AK and Beger HG (1996) The role of anti-p53-autoantibodies in pancreatic disorders. Int J Pancreatol 19: 171–178

Hall PA, Ray A, Lemoine NR, Midgley CA, Krauz T and Lane DP (1991) p53 immunostaining is a marker of malignancy in diagnostic cytopathology. Lancet 338: 513–515

Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816

Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancers. Science 253: 49–53

Kastan MB, Zhan Q, El Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597

Kern SE, Kinzler KW, Bruskin A, Jarroz D, Friedman P, Prives C and Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708–1711

Lee CS, Rush M, Charalambous D and Rode J (1993) Alimentary tract and pancreas: immunohistochemical demonstration of the p53 tumor suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterol Hepatol 8: 465–469

Melhem MF, Law JC, El-Ashmawy L, Johnson JT, Landreneau RJ, Srivastava S and Whiteside TL (1995) Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 146: 1170–1177

Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391–3395

Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sogiu T, Aiyoshi Y, Takahashi T, Ueda R and Takahashi T (1996) Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 14: 497–502

Ory K, Legros Y, Auguin C and Soussi T (1994) Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496–3504

Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW and Elledge SJ (1995) p53-independent expression of p21Cip1 in muscle and other terminal differentiating cells. Science 267: 1024–1027

Pellegrata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E and Ranzani GN (1994) K-ras and p53 gene mutations in pancreatic cancer: ductal and non-ductal tumours progress through different genetic lesions. Cancer Res 54: 1556–1560

Redston MS, Caldas C, Seymour AB, Hruban RH, Da Costa L, Yeo CJ and Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54: 3025–3033

Searpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C and Hirohashi S (1993) Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 142: 1534–1543

Schwaller J, Koehler HP, Niklaus G, Loetscher P, Nagel S, Fey MF and Tobler A (1995) Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SD1 in differentiating human leukemic cells. J Clin Invest 95: 973–979

Sibohara M, El Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B and Koehler HP (1994) Absence of WAF1 mutations in a variety of human malignancies. Blood 84: 3781–3784

Vogelstein B and Kinzler KW (1992) p53 function and dysfunction. Cell 70: 523–528

Wynford-Thomas D (1992) p53 in tumor pathology: can we trust immunocytochemistry? J Pathol 166: 329–330

Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704